Molecular roles of MAP kinases and FADD phosphorylation in prostate cancer

Histology and Histopathology

Volumn 21, Issue 4-6, 2006, Pages 415-422

  Shimada, K ^a   Nakamura, M ^a   Ishida, E ^a   Konishi, Noboru ^a  

^a NARA MEDICAL UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

Apoptosis; FADD phosphorylation; MAP kinase; Prostate cancer

Indexed keywords

ANDROGEN RECEPTOR; ANTINEOPLASTIC AGENT; CISPLATIN; ETOPOSIDE; FAS ASSOCIATED DEATH DOMAIN PROTEIN; GROWTH FACTOR; MITOGEN ACTIVATED PROTEIN KINASE; PACLITAXEL; PROTEIN SERINE THREONINE KINASE; STRESS ACTIVATED PROTEIN KINASE; SYNAPTOPHYSIN; FADD PROTEIN, HUMAN; GROWTH PROMOTOR; MITOGEN ACTIVATED PROTEIN KINASE P38; SIGNAL TRANSDUCING ADAPTOR PROTEIN;

APOPTOSIS; CANCER CHEMOTHERAPY; CELL CYCLE; CELL PROLIFERATION; CELL SURVIVAL; CHEMOSENSITIVITY; CORRELATION FUNCTION; ENZYME ACTIVATION; GENE EXPRESSION REGULATION; HUMAN; MITOSIS; MOLECULAR BIOLOGY; NONHUMAN; PATHOLOGY; PROSTATE CANCER; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN PHOSPHORYLATION; PROTEIN TARGETING; REGULATORY MECHANISM; REVIEW; SIGNAL TRANSDUCTION; STEM CELL; STRESS; TUMOR CELL; CANCER INVASION; ENZYMOLOGY; GENETICS; MALE; METABOLISM; PHOSPHORYLATION; PHYSIOLOGY; PROSTATE TUMOR;

ADAPTOR PROTEINS, SIGNAL TRANSDUCING; APOPTOSIS; CELL CYCLE; CELL PROLIFERATION; EXTRACELLULAR SIGNAL-REGULATED MAP KINASES; FAS-ASSOCIATED DEATH DOMAIN PROTEIN; GENE EXPRESSION REGULATION, NEOPLASTIC; GROWTH SUBSTANCES; HUMANS; JNK MITOGEN-ACTIVATED PROTEIN KINASES; MALE; MAP KINASE SIGNALING SYSTEM; MITOGEN-ACTIVATED PROTEIN KINASES; NEOPLASM INVASIVENESS; P38 MITOGEN-ACTIVATED PROTEIN KINASES; PHOSPHORYLATION; PROSTATIC NEOPLASMS; RECEPTORS, ANDROGEN;

EID: 33644837843     PISSN: 02133911     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (50)

1. Aguirre-Ghiso J.A., Liu D., Mignatti A., Kovalski K. and Ossowski L. (2001). Urokinase receptor and fibronectin regulate the ERK(MAPK) to p38(MAPK) activity ratios that determine carcinoma cell proliferation or dormancy in vivo. Mol. Biol. Cell 12, 863-879.
2. Bagrodia S., Derijard B., Davis R.J. and Cerione R.A. (1995). Cdc42 and PAK-mediated signaling leads to Jun kinase and p38 mitogen-activated protein kinase activation. J. Biol. Chem. 270, 27995-27998.
3. Bevan C.L., Hoare S., Claessens F., Heery D.M. and Parker M.G. (1999). The AF1 and AF2 domains of the androgen receptor interact with distinct regions of SRC1. Mol. Cell. Biol. 19, 8383-8392.
4. Brown J.L., Stowers L., Baer M., Trejo J., Coughlin S. and Chant J. (1996). Human Ste20 homologue hPAK1 links GTPases to the JNK MAP kinase pathway. Curr. Biol. 6, 59B-605.
5. Chang H.Y., Nishitoh H., Yang X., Ichijo H. and Baltimore D. (1998). Activation of apoptosis signal-regulating kinase 1 (ASK1) by the adapter protein Daxx. Science 281, 1860-1863.
6. Chen L., He H.Y., Li H.M., Zheng J., Heng W.J., You J.F. and Fang W.G. (2004). ERK1/2 and p38 pathways are required for P2Y receptor-mediated prostate cancer invasion. Cancer Lett. 215, 239-247.
7. Davis R.J. (2000). Signal transduction by the JNK group of MAP kinases. Cell 103, 239-252.
8. Davoodpour P. and Landstrom M. (2005). 2-Methoxyestradiol-induced apoptosis in prostate cancer cells requires Smad7. J. Biol. Chem. 280, 14773-14779.
9. de Souza P.L., Castillo M. and Myers C.E. (1997). Enhancement of paclitaxel activity against hormone-refractory prostate cancer cells in vitro and in vivo by quinacrine. Br. J. Cancer 75, 1593-1600.
10. Denmeade S.R., Lin X.S. and Isaacs J.T. (1996). Role of programmed (apoptotic) cell death during the progression and therapy for prostate cancer. Prostate 28, 251-265.
11. Dews M., Prisco M., Peruzzi F., Romano G., Morrione A. and Baserga R. (2000). Domains of the insulin-like growth factor I receptor required for the activation of extracellular signal-regulated kinases. Endocrinology 141, 1289-1300.
12. Dong C., Davis R.J. and Flavell R.A. (2002). MAP kinases in the immune response. Annu. Rev. Immunol. 20, 55-72.
13. Fanger G.R., Johnson N.L. and Johnson G.L. (1997). MEK kinases are regulated by EGF and selectively interact with Rac/Cdc42. EMBO J. 16, 4961-4972.
14. Fukazawa T., Fujiwara T., Morimoto Y., Shao J., Nishizaki M., Kadowaki Y., Hizuta A., Owen-Schaub L.B., Roth J.A. and Tanaka N. (1999). Differential involvement of the CD95 (Fas/APO-1) receptor/ligand system on apoptosis induced by the wild-type p53 gene transfer in human cancer cells. Oncogene 18, 2189-2199.
15. Gioeli D., Mandell J.W., Petroni G.R., Frierson H.F. Jr. and Weber M.J. (1999). Activation of mitogen-activated protein kinase associated with prostate cancer progression. Cancer Res. 59, 279-284.
16. Grosch S., Tegeder I., Schilling K., Maier T.J., Niederberger E. and Geisslinger G. (2003). Activation of c-Jun-N-terminal-kinase is crucial for the induction of a cell cycle arrest in human colon carcinoma cells caused by flurbiprofen enantiomers. Faseb J. 17, 1316-1318.
17. Grossmann M.E., Huang H. and Tindall D.J. (2001). Androgen receptor signaling in androgen-refractory ldrostate cancer. J. Natl. Cancer Inst. 93, 1687-1697.
18. Haq R., Halupa A., Beattie B.K., Mason J.M., Zanke B.W. and Barber D.L. (2002). Regulation of erythropoietin-induced STAT serine phosphorylation by distinct mitogen-activated protein kinases. J. Biol. Chem. 277, 17359-17366.
19. Hayes S.A., Huang X., Kambhampati S., Platanias L.C. and Bergan R.C. (2003). p38 MAP kinase modulates Smad-dependent changes in human prostate cell adhesion. Oncogene 22, 4841-4850.
20. Hemmi A., Komiyama A., Ohno S., Fujii Y., Katoh R., Yokoyama A. and Kawaoi A. (1998). Poorly differentiated desmin-negative and vimentin-positive leiomyosarcoma of the stomach examined by the immunohistochemical and quick-freezing and deep-etching methods. Virchows Arch. 432, 377-383.
21. Ichijo H., Nishida E., Irie K., ten Dijke P., Saitoh M., Moriguchi T., Takagi M., Matsumoto K., Miyazono K. and Gotoh Y. (1997). Induction of apoptosis by ASK1, a mammalian MAPKKK that activates SAPK/JNK and p38 signaling pathways. Science 275, 90-94.
22. Ip Y.T. and Davis R.J. (1998). Signal transduction by the c-Jun N-terminal kinase (JNK) - from inflammation to development. Curr. Opin. Cell Biol. 10, 205-219.
23. Karhadkar S.S., Bova G.S., Abdallah N., Dhara S., Gardner D., Maitra A., Isaacs J.T., Berman D.M. and Beachy P.A. (2004). Hedgehog signalling in prostate regeneration, neoplasia and metastasis. Nature 431, 707-712.
24. Lee K.H., Choi E.Y., Hyun M.S. and Kim J.R. (2004). Involvement of MAPK pathway in hypoxia-induced up-regulation of urokinase plasminogen activator receptor in a human prostatic cancer cell line, PC3MLN4. Exp. Mol. Med. 36, 57-64.
25. Lee Y.F., Lin W.J., Huang J., Messing E.M., Chan F.L., Wilding G. and Chang C. (2002). Activation of mitogen-activated protein kinase pathway by the antiandrogen hydroxyflutamide in androgen receptor-negative prostate cancer cells. Cancer Res. 62, 6039-6044.
26. Malik S.N., Brattain M., Ghosh P.M., Troyer D.A., Prihoda T., Bedolla R. and Kreisberg J.I. (2002). Immunohistochemical demonstration of phospho-Akt in high Gleason grade prostate cancer. Clin. Cancer Res. 8, 1168-1171.
27. Maroni P.D., Koul S., Meacham R.B. and Koul H.K. (2004). Mitogen Activated Protein kinase signal transduction pathways in the prostate. Cell Commun. Signal 2, 5.
28. Molnar A., Theodoras A.M., Zon L.I. and Kyriakis J.M. (1997). Cdc42Hs, but not Rac1, inhibits serum-stimulated cell cycle progression at G1/S through a mechanism requiring p38/RK. J. Biol. Chem. 272, 13229-13235.
29. Park J.I., Lee M.G., Cho K., Park B.J., Chae K.S., Byun D.S., Ryu B.K., Park Y.K. and Chi S.G. (2003). Transforming growth factor-beta1 activates interleukin-6 expression in prostate cancer cells through the synergistic collaboration of the Smad2, p38-NF-kappaB, JNK, and Ras signaling pathways. Oncogene 22, 4314-4332.
30. Paweletz C.P., Charboneau L., Bichsel V.E., Simone N.L., Chen T., Gillespie J.W., Emmert-Buck M.R., Roth M.J., Petricoin I.E. and Liotta L.A. (2001). Reverse phase protein microarrays which capture disease progression show activation of pro-survival pathways at the cancer invasion front. Oncogene 20, 1981-1989.
31. Pombo C.M., Kehrl J.H., Sanchez I., Katz P., Avruch J., Zon L.I., Woodgett J.R., Force T. and Kyriakis J.M. (1995). Activation of the SAPK pathway by the human STE20 homologue germinal centre kinase. Nature 377, 750-754.
32. Potapova O., Gorospe M., Dougherty R.H., Dean,N.M., Gaarde W.A. and Holbrook N.J. (2000). Inhibition of c-Jun N-terminal kinase 2 expression suppresses growth and induces apoptosis of human tumor cells in a p53-dependent manner. Mol. Cell Biol. 20, 1713-1722.
33. Putz T., Culig Z., Eder I.E., Nessler-Menardi C., Bartsch G., Grunicke H., Uberall F. and Klocker H. (1999). Epidermal growth factor (EGF) receptor blockade inhibits the action of EGF, insulin-like growth factor I, and a protein kinase A activator on the mitogen-activated protein kinase pathway in prostate cancer cell lines. Cancer Res. 59, 227-233.
34. Ritchie C.K., Andrews L.R., Thomas K.G., Tindall D.J. and Fitzpatrick L.A. (1997). The effects of growth factors associated with osteoblasts on prostate carcinoma proliferation and chemotaxis: implications for the development of metastatic disease. Endocrinology 138, 1145-1150.
35. Roudabush F.L., Pierce K.L., Maudsley S., Khan K.D. and Luttrell L.M. (2000). Transactivation of the EGF receptor mediates IGF-1-stimulated shc phosphorylation and ERK1/2 activation in COS-7 cells. J. Biol. Chem. 275, 22583-22589.
36. Scaffidi C., Volkland J., Blomberg I., Hoffmann I., Krammer P.H. and Peter M.E. (2000). Phosphorylation of FADD/MORT1 at serine 194 and association with a 70-kDa cell cycle-regulated protein kinase. J. Immunol. 164, 1236-1242.
37. She Q.B., Chen N., Bode A.M., Flavell R.A. and Dong Z. (2002). Deficiency of c-Jun-NH(2)-terminal kinase-1 in mice enhances skin tumor development by 12-O-tetradecanoylphorbol-13-acetate. Cancer Res. 62, 1343-1348.
38. Shimada K., Nakamura M., Ishida E., Kishi M. and Konishi N. (2003). Roles of p38- and c-jun NH2-terminal kinase-mediated pathways in 2-methoxyestradiol-induced p53 induction and apoptosis. Carcinogenesis 24, 1067-1075.
39. Shimada K., Matsuyoshi S., Nakamura M., Ishida E., Kishi M. and Konishi N. (2004). Phosphorylation of FADD is critical for sensitivity to anticancer drug-induced apoptosis. Carcinogenesis 25, 1089-1097.
40. Shimada K., Matsuyoshi S., Nakamura M., Ishida E. and Konishi N. (2005). Phosphorylation status of Fas-associated death domain-containing protein (FADD) is associated with prostate cancer progression. J. Pathol. 206, 423-432.
41. Tanaka Y., Gavrielides M.V., Mitsuuchi Y., Fujii T. and Kazanietz M.G. (2003). Protein kinase C promotes apoptosis in LNCAP prostate cancer cells through activation of p38 MAPK and inhibition of the Akt survival pathway. J. Biol. Chem. 278, 33753-33762.
42. Ueda T., Mawii N.R., Bruchovsky N. and Sadar M.D. (2002). Ligand-independent activation of the androgen receptor by interleukin-6 and the role of steroid receptor coactivator-1 in prostate cancer cells. J. Biol. Chem. 277, 38087-38094.
43. Unni E., Sun S., Nan B., McPhaul M.J., Cheskis B., Mancini M.A. and Marcelli M. (2004). Changes in androgen receptor nongenotropic signaling correlate with transition of LNCaP cells to androgen independence. Cancer Res. 64, 7156-7168.
44. Uzgare A.R. and Isaacs J.T. (2004). Enhanced redundancy in Akt and mitogen-activated protein kinase-induced survival of malignant versus normal prostate epithelial cells. Cancer Res. 64, 6190-6199.
45. Uzgare A.R., Kaplan P.J. and Greenberg N.M. (2003). Differential expression and/or activation of P38MAPK, erk1/2, and jnk during the initiation and progression of prostate cancer. Prostate 55, 128-139.
46. Vayalil P.K., Mittal A. and Katiyar S.K. (2004). Proanthocyanidins from grape seeds inhibit expression of matrix metalloproteinases in human prostate carcinoma cells, which is associated with the inhibition of activation of MAPK and NF kappa B. Carcinogenesis 25, 987-995.
47. Wada T. and Penninger J.M. (2004). Mitogen-activated protein kinases in apoptosis regulation. Oncogene 23, 2838-2849.
48. Wilkinson M.G. and Millar J.B. (1998). SAPKs and transcription factors do the nucleocytoplasmic tango. Genes Dev. 12, 1391-1397.
49. Xia Z., Dickens M., Raingeaud J., Davis R.J. and Greenberg M.E. (1995). Opposing effects of ERK and JNK-p38 MAP kinases on apoptosis. Science 270, 1326-1331.
50. Yang Y.M., Bost F., Charbono W., Dean N., McKay R., Rhim J.S., Depatie C. and Mercola D. (2003). C-Jun NH(2)-terminal kinase mediates proliferation and tumor growth of human prostate carcinoma. Clin. Cancer Res. 9, 391-401.